What the New Statin Guidelines Mean for People Over 70

The headline version of the new statin guidance sounds startling: under the 2026 ACC/AHA dyslipidemia guideline, an estimated 93.5% of U.S. adults ages 70–79 without prior cardiovascular disease are now eligible for statin consideration, compared with roughly 40% under the 2018 rule.[1] That is the number likely to make an adult child look up from the phone and wonder whether a parent’s next appointment is about to become automatic.

It is not automatic. In this guideline, “eligible” does not mean “should be handed a prescription before leaving the office.” It means the person meets criteria for a clinician-patient discussion about whether a statin makes sense after looking at estimated risk, age, current medications, coronary artery calcium, other health conditions, preferences, and the tradeoffs of adding or continuing a daily drug.

That distinction matters most for families trying to interpret statin eligibility for older parents under the new guidelines. The practical question is not whether every person over 70 should start a statin. It is what to ask before starting one, continuing one, or deciding not to use one.

What changed in the 2026 guideline

The large jump in eligibility comes from two related changes. First, the guideline extends routine risk assessment from the prior 40–75 age range to ages 30–79. Second, it replaces the older Pooled Cohort Equations with the PREVENT-ASCVD calculator.[2]

PREVENT is not just the same cholesterol-and-age math with a new name. It uses broader health inputs, including kidney function and whether the person is already taking statin or blood pressure medication. At the same time, analyses cited in coverage of the new guideline found that PREVENT produces risk estimates roughly 40–50% lower than the older calculator for the same profile.[1]

That can sound contradictory: how can a calculator estimate lower risk and still pull many more older adults into eligibility? The answer is that eligibility is shaped not only by the risk number but also by who is being assessed. Adults ages 76–79, who were outside the older routine risk-assessment range, are now inside the calculator’s age span. For people in their 70s, age still carries enough cardiovascular risk weight that many cross a threshold for discussion even when the newer calculator estimates their risk more conservatively.

For a clinic visit, the change is simple to translate: ask what the parent’s PREVENT-calculated 10-year risk is, what inputs were used, and whether the result is being treated as a reason to discuss a statin or as a reason to recommend one strongly.

Eligibility is a doorway, not a verdict

The guideline’s tone becomes more cautious after age 75. For primary prevention in adults over 75—that is, preventing a first cardiovascular event—the 2026 ACC/AHA guideline gives a weaker recommendation, classified as COR 2a, because randomized trial data in this age group remain limited.[2]

That weaker recommendation is not a warning label saying statins are inappropriate after 75. It means the evidence is not as firm as it is for younger groups, and the decision needs more individual judgment. A healthy 76-year-old with a high estimated risk, good medication tolerance, and a strong preference to prevent a heart attack may land in a different place than an 86-year-old with frailty, medication side effects, and priorities centered on simplifying care.

The questions worth asking at the appointment

A statin conversation for an older adult can go off track if it begins and ends with a single cholesterol number. Cholesterol still matters, but the new guideline is built around overall cardiovascular risk, not age or LDL cholesterol alone.

• What is the PREVENT-calculated 10-year cardiovascular risk, and which information was entered into the calculator?
• Is this a primary-prevention decision, or has the parent already had a heart attack, stroke, stent, bypass surgery, or another cardiovascular event?
• If the parent is over 75, how strong is the recommendation in this specific case?
• Would a coronary artery calcium scan change the decision?
• If the parent already takes a statin, what is the reason to continue, lower the dose, switch drugs, or stop?
• What side effects, drug interactions, cost issues, or pill-burden concerns should be watched for?

Those questions do not push the answer in one direction. They slow the decision down enough to keep “eligible” from being mistaken for “obligated,” while also avoiding the opposite mistake: dismissing prevention simply because a person is older.

Where CAC scoring can change the conversation

Coronary artery calcium, or CAC, scoring is a CT-based measure of calcified plaque in the coronary arteries. In the older-adult statin discussion, it is most useful when the risk estimate and the person’s preferences do not clearly point the same way.

The most practical detail for many families is that a CAC score of zero in an older adult can tip the balance away from starting a statin, especially when the decision is for primary prevention and there is no prior cardiovascular disease.[1] It does not erase all risk, and it does not answer every question, but it can help distinguish a person whose age makes the calculator look concerning from a person whose coronary arteries show little calcified plaque at that moment.

A CAC scan is not necessary for every older adult considering a statin. It is a tie-breaker, not a ritual. It may be most helpful when the parent is reluctant to add medication, the clinician is uncertain how much benefit to expect, or the family is trying to make a decision that fits both the risk estimate and the person’s day-to-day priorities.

Starting is different from stopping

A parent who is already taking a statin is not in the same situation as a parent being offered one for the first time. Continuing a tolerated medication has a different risk-benefit shape than adding a new pill to an already crowded list.

That does not mean statins should never be stopped after 75. It does mean stopping should be treated as a decision with consequences, not as a casual cleanup because the person has crossed a birthday. CNN’s coverage of the guideline noted that multiple European cohort studies found higher cardiovascular event rates after statin discontinuation in adults over 75.[3]

Cohort studies can show an association; they do not prove that stopping the statin caused every later event. People who discontinue a medication may differ from those who continue it in ways that are hard to fully separate. Still, the finding is enough to make abrupt deprescribing feel too casual, especially when the medication has been tolerated for years.

The better question is specific: what problem is stopping meant to solve? Muscle symptoms, drug interactions, worsening frailty, limited life expectancy, cost, swallowing difficulty, and patient preference can all be legitimate reasons to revisit therapy. But “he is old now” is not a clinical reason by itself.

What changes after 80

The PREVENT equations apply through age 79; they do not apply to adults ages 80 and older.[1] For the oldest patients, the guideline conversation becomes less calculator-driven. Clinicians may still consider cholesterol levels, blood pressure, diabetes, kidney disease, smoking history, prior test results, CAC scoring when appropriate, medication tolerance, frailty, and goals of care, but the decision rests more heavily on judgment.

That limit should be visible in the appointment. If a parent is 82, it is fair to ask whether any risk number being discussed came from a calculator validated for that age. If not, the conversation should shift from a numeric threshold to the clinician’s reasoning: what risk is being reduced, over what time horizon, with what expected burden, and how that fits the person’s health priorities.

The evidence gap after 75 is real

The cautious wording for adults over 75 reflects a real evidence gap, not indifference. Randomized trial evidence for primary-prevention statin therapy is more limited beyond age 75, which is why ongoing trials matter.[2]

Two major trials are expected to add clarity: STAREE in Australia, enrolling adults ages 70 and older, and PREVENTABLE in the United States, enrolling adults ages 75 and older. Results are expected through 2026–2027.[4]

Until those results are available and incorporated into future guidance, families should expect some uncertainty in primary-prevention decisions after 75. Uncertainty does not mean guessing. It means the clinician should be able to explain why the balance leans toward starting, continuing, adjusting, or not using a statin for this particular person.

A practical way to read the new eligibility number

The 93.5% figure for ages 70–79 is important because it tells families that many older adults who were not previously captured by the older guideline framework may now be brought into a statin conversation.[1] It should not be read as proof that nearly every person in that decade must take one.

For a parent in their 70s, the new guideline opens the door wider. The decision still has to pass through the narrower space of individualized risk assessment: the PREVENT estimate, the person’s prior cardiovascular history, CAC results when useful, current statin use, tolerance, competing health issues, and what the person values enough to add or keep a medication.

Age should start the conversation, not finish it. Cholesterol should inform the conversation, not carry it alone. For older adults and the people who help them through appointments, the most useful response to the new guideline is neither alarm nor dismissal, but a prepared question: based on this person’s actual risk and health situation, what are we trying to prevent, and is a statin the right tool now?

References

1. More than half of US adults now qualify for statins under new guidelines, Michigan Medicine
2. 2026 ACC/AHA Guideline for the Management of Patients With Dyslipidemia, American Heart Association
3. Statin eligibility under new guidelines, CNN, July 27, 2026
4. Primary Prevention Statin Therapy in Older Adults, PMC/NIH